BioSpace News Archive

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, hosted members of Congress focused on strengthening the U.S. bioeconomy in service of national and economic security yesterday.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the U.S. Food and Drug Administration (FDA) has extended the Priority Review period for the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I (LAD-I).

Incyte (Nasdaq:INCY) today reports 2023 fourth quarter financial results, provides 2024 financial guidance and provides a status update on the Company’s research and development portfolio.

Precision BioSciences, Inc. today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations.

Satellos Bioscience Inc. announced positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy.

Nicoya®, a pioneering life science instrument company specializing in innovative biosensor technology, is pleased to announce the appointment of Medispec as its exclusive distributor in India.

MediPrint Ophthalmics, a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, proudly announced the appointment of Thomas Bender as a strategic advisor.

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2023.

Avicanna Inc. is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by INVIMA, the Health Authority of Colombia.

Candel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate.